Ann: Oncosil breakthrough device receives CE Marking approval, page-161

Bell Potter reckon Oncosil can achieve circa $1 million in sales every month following the launch later in the year. This is conservative and only reflects take up at around 20 sites. Bell’s reckon this revenue is just from one or two procedures per month from each of the 20 sites.

So, even from just a modest launch later in the year, they are talking of annual revenue of over $10 million. Bell’s also reckon that commercial validation will occur soon after the launch.

Bell’s has raised price target to 42 cents similar to Wilson’s.


Cheers

GW